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BNC2 is a putative tumor suppressor gene in
high-grade serous ovarian carcinoma and impacts
cell survival after oxidative stress
Laura Cesaratto1,9, Eleonora Grisard1,9, Michela Coan1,2, Luigi Zandonà1, Elena De Mattia3, Elena Poletto4, Erika Cecchin3,
Fabio Puglisi4,5, Vincenzo Canzonieri6, Maria Teresa Mucignat1, Antonella Zucchetto7, Gabriele Stocco8, Alfonso Colombatti1,
Milena S Nicoloso*,1 and Riccardo Spizzo*,1
Rs3814113 is the single-nucleotide polymorphism (SNP) showing the strongest association with high-grade serous ovarian
carcinoma (HGSOC) incidence and is located in an intergenic region about 44 kb downstream of basonuclin 2 (BNC2) gene.
Lifetime number of ovulations is associated with increased risk to develop HGSOC, probably because of cell damage of
extrauterine Müllerian epithelium by ovulation-induced oxidative stress. However, the impact of low-penetrance HGSOC risk alleles
(e.g. rs3814113) on the damage induced by oxidative stress remains unclear. Therefore, the purpose of this study was to
investigate whether rs3814113 genetic interval regulates BNC2 expression and whether BNC2 expression levels impact on cell
survival after oxidative stress. To do this, we analyzed gene expression levels of BNC2 first in HGSOC data sets and then in an
isogenic cell line that we engineered to carry a 5 kb deletion around rs3814113. Finally, we silenced BNC2 and measured surviving
cells after hydrogen peroxide (H2O2) treatment to simulate oxidative stress after ovulation. In this paper, we describe that BNC2
expression levels are reduced in HGSOC samples compared with control samples, and that BNC2 expression levels decrease
following oxidative stress and ovulation in vitro and in vivo, respectively. Moreover, deletion of 5 kb surrounding rs3814113
decreases BNC2 expression levels in an isogenic cell line, and silencing of BNC2 expression levels increases cell survival after
H2O2 treatment. Altogether, our findings suggest that the intergenic region located around rs3814113 regulates BNC2 expression,
which in turn affects cell survival after oxidative stress response. Indeed, HGSOC samples present lower BNC2 expression levels
that probably, in the initial phases of oncogenic transformation, conferred resistance to oxidative stress and ultimately reduced the
clearance of cells with oxidative-induced damages.
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Epithelial ovarian cancer (EOC) is a relatively uncommon
tumor accounting for ~ 2.6% of newly diagnosed tumors in
2015 in the United States; however, EOC is the fifth most
common cause of cancer death in women in the United States
and in the Western countries, and the first among gyneco-
logical tumors.1 High-grade serous ovarian carcinoma
(HGSOC) is the single largest group of EOC and the histotype
that accounts for almost two-thirds of ovarian cancer deaths.
HGSOC is typically diagnosed in postmenopausal age and at
advanced clinical stages (III and IV), mainly owing to the lack
of early symptoms and of affordable screening programs
applicable to the general population.2 For these reasons, it is
urgent to discover the key molecular events that predispose
to and/or occur in the early phases of HGSOC oncogenic
transformation, which are necessary for the development of
effective screening tools, chemoprevention programs3,4 and
eventually novel anticancer therapies.5
Recent reports elucidated novel details about the origin of
HGSOC: studies from women carrying BRCA1/2 mutations
identified tubal intraepithelial carcinoma in the distal fimbriated
end of the fallopian tube as the probable precursor lesion of
HGSOC.6 This may also occur in the secondary Müllerian
system locations (e.g. ovary and peritoneum) that, along with
fallopian tube, belong to the extrauterineMüllerian epithelium.7,8
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In HGSOC, the most important risk factor is the occurrence
of the disease in a first-degree relative;9 this excess of risk is
because of both environmental (e.g. lifetime number of
ovulations, body mass index and so on) and genetic factors.
Concerning environmental factors, lifetime number of ovula-
tions was one of the first to be described,10 and rodent models
of repeated superovulation confirmed the insurgence of
modifications resembling early transformation.11,12 The expla-
nation of the association between lifetime number of ovula-
tions and HGSOC incidence may reside in cell damage by
ovulation-induced oxidative stress.11,13 Concerning genetic
risk factors, which have the greatest impact, less than half
of the excess of risk is due to BRCA1/2 high penetrance
mutations, whereas the remaining risk is probably because of
low- to moderate-penetrance risk alleles.14 Low- to moderate-
penetrance risk alleles (e.g. single-nucleotide polymorphism
(SNP)) can be identified by genome-wide association studies
(GWAS)15 and ultimately give novel molecular insights on
tumor biology.16–18
SNP rs3814113 has the strongest association with HGSOC
incidence14 and is located in an intergenic region of human
9p22.2 locus, ~ 44 kb downstream from the transcription
starting point (TSS) of basonuclin 2 (BNC2) gene and
~200 kb upstream from TSS of centlein (CNTLN) gene.
BNC2 transcribes a zinc-finger protein highly conserved
during evolution,19 with about 200 transcript isoforms,20
and BNC2-knockout (KO) mice die within 24 h after birth.21
Preliminary evidences pointed to BNC2 as the coding
transcript that could be responsible for the association
between 9p22.2 locus and HGSOC: BNC2 promoter is more
frequently methylated in peripheral lymphomonocytes of EOC
patients compared with healthy subjects,22 BNC2 expression
levels are reduced in EOC cell lines compared with primary
human ovarian surface epithelial cell cultures,23 and BNC2
was described as a presumptive tumor suppressor gene in
bladder, esophageal and glioblastoma tumors.24–26
The impact of low-penetrance HGSOC risk alleles (e.g.
rs3814113) on cell damage induced by oxidative stress remains
unclear. For instance, acquired genetic modifications, which
reduce cell death after oxidative stress, may offer fallopian
serous epithelial cells the advantage to survive despite carrying
genetic damages caused by oxidative stress exposure.12
Therefore, the purpose of this study was to investigate whether
rs3814113 genetic interval regulates BNC2 expression and
whether BNC2 expression levels impact cell survival after
oxidative stress. To do this, first we engineered an isogenic cell
line to carry a 5 kb deletion around rs3814113 and measured
BNC2 levels; next, we silenced BNC2 expression levels, and
after hydrogen peroxide (H2O2) treatment, which simulates
oxidative stress after ovulation,11 we measured cell survival.
Results
BNC2 is in linkage with rs3814113 and is a putative tumor
suppressor in HGSOC. To consolidate that BNC2 is the
principal actor of the association between human 9p22.2
locus and HGSOC incidence, we used two independent
strategies. First, we searched for SNPs in linkage disequili-
brium (LD) with rs3814113 by using SNAP bioinformatics
tool,27 and we discovered that rs3814113 is correlated
(r2≥0.8) to other 11 SNPs located within 6.8 kb upstream
(Figure 1a and Supplementary Table 1). Yet, recombination
rates suggested a larger haplotypic block, which includes the
first exon and intron of BNC2, embracing one of BNC2
promoters, and includes additional SNPs that correlated to
rs3814113 with an r2≥0.5 (Figure 1a and Supplementary
Table 1). Within the identified haplotypic block, rs3814113
was the only SNP present in the Illumina SNP-chromatin
immunoprecipitation (ChIP) array used in the GWAS
study that initially correlated 9p22.2 region with EOC pre-
disposition.14
In the second strategy, we searched for genes within the
9p22.2 locus differentially expressed between tumor-free
control and HGSOC samples. To do this, we interrogated the
gene data set by Tone et al.,28 which analyzed microdissected
non-malignant fallopian tube epithelium (FTE) and HGSOC
samples using a high-density Affymetrix gene expression
array (Affymetrix Human Genome U133 Plus 2.0 Array, Santa
Clara, CA, USA). We correlated signal intensity levels of
microarray probes located within ±4 Mb from rs3814113
(Supplementary Figure S1A) with the sample type (i.e. FTE or
HGSOC samples), and we found that BNC2 locus was the
region with the greatest number of probes inversely correlated
with HGSOC (i.e. lower signal intensity in HGSOC compared
with non-malignant FTE samples) (Supplementary
Figure S1B and Figure 1b). Instead, CNTLN, which is the
closest gene downstream of rs3814113, was not differentially
expressed between the groups (Figure 1b). We confirmed
these results in a second publically available data set29
(Figure 1c). Meanwhile, we collected at our Institute an original
cohort of HGSOC and tumor-free control samples (fallopian
tube and ovarian), in which we confirmed by quantitative real-
time PCR (qRT-PCR) that BNC2 expression was reduced in
HGSOC (Figure 1d). Therefore, both LD and gene expression
data analyses pointed to BNC2 as the most likely candidate
genetic element involved in HGSOC predisposition.
Next, we measured BNC2 transcript expression in a panel
of 16 EOC cell lines (Figure 2a). By grouping EOC cells into
likely and unlikely HGSOC,30 we did not observe any
significant difference in BNC2 expression levels between the
two groups. In seven likely HGSOC cell lines, BNC2 protein
expression was proportional tomRNAexpression and showed
several isoforms between 100 and 150 kDa (Figure 2b);
moreover, BNC2 was localized exclusively in the NP40
nuclear insoluble fraction (Supplementary Figures S2A
and B) in agreement with Vanhoutteghem and Djian.19
Interestingly, of the 12 EOC cell lines that we genotyped for
rs3814113, all carried the T allele in homozygosis (data not
shown), which is the allele associated with increased EOC
predisposition in the general population,14 whereas according
to dbSNP build 141,31 the expected frequency for rs3814113
in the general population is 58% for T and 42% for C.
According to Vanhoutteghem and Djian20 and Ghanbari
et al.,32 BNC2 has several putative promoters and enhan-
cers, which is also confirmed by the Encode project33
(Supplementary Figure S3); however, histone marks enriched
in promoters and enhancers (H3K4me3 and H3K27Ac,
respectively) have never been described in HGSOC cell
models. Therefore, we performed ChIP for these histone
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marks in OV90, OVCAR4 and COV318 EOC cell lines.
Consistent with BNC2 mRNA and protein expression levels
(Figures 2a and b), histone mark enrichment in candidate
genetic regions was almost absent in OV90, intermediate in
OVCAR4 and high in COV318 (Figure 2c). Moreover, in both
COV318 andOVCAR4, the region labeled asBNC2Prom2 had
the highest enrichment, in agreement with Ghanbari et al.32
To sum up, these data indicate that the genomic region in LD
(r2≥0.5) with rs3814113 includes one of the BNC2 promoters
and that BNC2 is downregulated in HGSOC samples
compared with non-malignant FTE samples.
A human genomic region including rs3814113 regulates
BNC2 expression. Interestingly, rs3814113 resides inside
AK024561 genomic locus, a putative non-coding RNA
transcript that was cloned in human adipose tissue according
to GenBank records (Figure 3a). Two probes of the Affymetrix
U133 Plus 2.0 Array hybridize to AK024561 (i.e. 216730_at
and 216742_at) (Supplementary Figure 3), but both show low
expression signals and no difference between non-malignant
FTE and HGSOC samples in Tone et al.28 (Figure 1b and
Supplementary Figure S1B). We evaluated expression levels
of AK024561 in a panel of 17 different non-malignant tissues,
including peripheral blood mononuclear cells (PBMCs)
collected from healthy donors, and in a panel of HGSOC
samples, fallopian tube and ovary tumor-free samples.
AK024561 was strongly expressed only in the testis20 and
moderately expressed in the adrenal gland and skeletal
muscle (Figure 3b). Only in 4 out of 10 HGSOC tumor
samples, we could detect a faint band, whereas we did not
F
Figure 1 Rs3814113 at chromosome 9p22.2 is in linkage with BNC2, a putative tumor suppressor gene in HGSOC. (a) Regional LD plot generated using the SNPAnnotation
and Proxy Search web interface using rs3814113 as target SNP (https://www.broadinstitute.org/mpg/snap/ldsearch.php). The left-hand y axis shows values for r2 (correlation
coefficient, a measure of LD; 0.8 was set as threshold), whereas the right-hand y axis shows recombination rate values in centiMorgans (units of recombination) per million bases
(cM/Mb). Diamond labels correspond to SNP (black diamond is rs3814113, gray filled diamonds represent SNPs with r2≥ 0.8 with rs3814113, empty filled diamonds have an
r2o0.8). Higher peaks of recombination rate indicate an association between rs314113 and the end of BNC2 genetic locus. (b) Analyses of gene expression for Affymetrix
probes surrounding rs3814113 in the 9p22.2 locus from the GSE10971 data set. Affymetrix probes are indicated by a number followed by ‘_at’. Laser capture microdissected non-
malignant distal FTE n= 24; HGSOC, n= 13. BNC2, intergenic region surrounding rs3814113, and CNTLN loci were represented in this array by 8, 2 and 4 probes, respectively.
Bars are mean± S.E. (c) Analyses of BNC2 and CNTLN expression in the GSE26712 data set. Non-malignant ovarian surface epithelium (OSE), n= 10; HGSOC, n= 185. In
this Affymetrix array, BNC2 and CNTLN were represented only by one probe (220272_at and 22095_at, respectively). Lines are mean± S.E. (d) qRT-PCR analysis of BNC2 and
CNTLN gene expression levels normalized by GAPDH in an original cohort of samples. Control samples= non-malignant ovarian and fallopian specimens, n= 4; HGSOC
samples, n= 10. Scatter dot plot bars indicate mean±S.E. **Po0.01; *Po0.05; ns, nonsignificant. t-Test assuming unequal variances was used for statistical analysis
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detect any band in the fallopian tube or ovarian healthy
samples, except in one sample obtained from the round
ligament (Figure 3b). We evaluated AK024561 expression in
several cell lines of mesodermal origin, the same origin of the
extrauterine Müllerian epithelium (COV318, COV504,
COV362, OVCAR4, 293FT, JURKAT, MAVER, MEC, EHEB,
HL60, RAJI, K562, SKUT-1, U2OS, HT1080, human
mesenchymal stem cells, MET5A), but none showed any
c
a b
Figure 2 BNC2 expression and genetic regulation. (a) qRT-PCR analysis of BNC2 expression in a panel of 16 ovarian cancer cell lines, grouped in likely and unlikely HGSOC.
(b) Western blot detection of BNC2 shows several isoforms in NP40-insoluble protein extracts from seven likely HGSOC cell lines. H2AX total was used as loading control.
(c) ChIP for histone mark enrichment (measured by qRT-PCR) in the putative promoter/enhancer genomic regions comprising BNC2, CNTLN and the intergenic region in
between, according to UCSC (Supplementary Figure S3). H3K4me3 (top panels) and H3K27Ac (bottom panels)= histone H3 trymethylated on lysine 4 and acetylated on lysine
27, respectively. BNC2 intron 2 (Intr 2) was set as 1
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detectable expression levels except COV318, which had an
extremely low signal (data not shown). Consistently, we did
not observe histone mark enrichment in the intergenic
regions including AK024561 locus and nearby enhancers
(intergenic enhancers 1, 2 and 3), except for a H3K27Ac
enrichment in OVCAR4 intergenic enhancers 1 and 3
(Figure 2c).
To investigate whether AK024561 locus may still regulate
BNC2 expression, we deleted 5 kb surrounding the SNP
(between guide 6 and guide 9 in Figure 3a) using CRISPR-
Cas9 system.17,34 Unfortunately, we could not obtain KO cell
clones in COV318, which is the only cell line, among the ones
that we tested, that expressed AK024561 (data not shown),
because of the low efficiency of COV318 to grow as single-cell
clones; therefore, we opted for 293FT because of very high
efficiency of transfection and of single-cell clone recovery. We
recovered five clones with homozygous deletion of the
targeted region (KO clones) (Figure 3c and Supplementary
Figure S4B), and we compared them with four wild-type (WT)
clones, which had either point mutations in guide RNA target
Figure 3 A human genomic region including rs3814113 regulates BNC2 expression. (a) Genomic view of the 6.6 kb, surrounding rs3814113, with annotated human mRNAs
from GenBank, according to UCSC genome browser. Positions for guides 6 and 9 (guide RNAs used for CRISPR (clustered regularly interspaced short palindromic repeat)
deletion of the region), for Screen 6F and Screen 7F (primers used for PCR screening of KO), and for AK 5+3 (amplicon used to detect AK024561 transcript) are indicated.
(b) Agarose gel of PCR with AK 5+3 primers to detect AK024561 in human samples: top panels, 14 normal human tissues and 3 PBMCs from healthy donors; bottom panels, 11
serous ovarian cancers (10 high grade, 1 low grade= LG) and 8 non-malignant control samples (4 fallopian tubes, 1 round ligament=RL, 3 ovaries). gDNA= genomic DNA used
as PCR positive control; RT-PCR on non-retrotranscribed RNA, to exclude genomic contamination; GAPDH and U6= housekeeping genes used for normalization.
(c) Representative agarose gel of PCR with Screen 6F+Screen 7R primer pair showing the deletion of the 5 kb region surrounding rs3814113. (d) qRT-PCR analysis of BNC2 and
CNTLN expression in 293FT KO cell clones. Points for WTand KO samples represent normalized expression data from four distinct WTand five distinct KO clones. The values for
each clone are the average of two biologically independent experiments. Three distinct primer pairs (encompassing BNC2’s exon 1-2, exon 2-2a and exon 6) were used to detect
BNC2 expression levels. t-Test assuming unequal variances was used for statistical analysis. Scatter dot plot bars indicate mean± S.E. *Po0.05. ns, nonsignificant
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sites (n=2) (guides 6 and 9 in Figure 3a) or no mutations
(n=2) (sequences provided in the Supplementary Material).
We measured BNC2 and CNTLN transcript expression
levels in WT and KO clones; given the multiplicity of BNC2
isoforms,20 we designed three qRT-PCR primer pairs that
target exon boundary 1-2, 2-2a and exon 620 (Supplementary
Figure S3). By these means, we observed that the dele-
tion of the 5 kb region comprising rs3814113 almost halved
expression levels of BNC2 but not of CNTLN (Figure 3d).
Unfortunately, 293FT expression levels of BNC2 protein
were almost undetectable and it was not possible to observe
any difference between WT and KO clones. Of note, in
293FT cells, rs3814113 is heterozygous (C/T) and AK024561
was never detected both in whole and nuclear RNA (data not
shown).
Taken together, these findings indicate that the genetic
region encompassing rs3814113 regulates BNC2 but not
CNTLN expression levels, and that this regulation does not
depend on AK024561 transcription.
Oxidative stress reduces BNC2 expression in vitro and
in vivo. The incessant ovulation model of EOC origin lies on
the hypothesis that fallopian tubes and ovaries are exposed
to increased levels of reactive oxygen species (ROS) during
ovulation cycle, which reiterated over time may generate
the soil for EOC insurgence.4,10,12 Therefore, to investigate
whether BNC2 may be involved in the incessant ovulation
model, we evaluated BNC2 expression levels following
oxidative stress. To simulate postovulation environment, we
treated OV90, COV318 and COV504 with increasing doses of
H2O2 and evaluated BNC2 levels at early and late time
points, after 3 h and 24 h, respectively.35 Effectiveness of
H2O2 cell treatment was verified by phosphorylation of H2AX
with no evident disparities among cell lines (Figure 4a and
Supplementary Figure 5). While in OV90 BNC2 levels
remained undetectable even after H2O2 treatment (data not
shown), in COV318 and COV504, we observed a dosage-
dependent reduction of BNC2 protein levels at 24 h after
treatment, but not at earlier time points. To understand
whether BNC2 reduction occurred both at the transcriptional
and protein level, we measured BNC2 by qRT-PCR and found
that, 5 h following H2O2 exposure, BNC2 transcript levels
were already halved, suggesting a regulation of BNC2 at the
transcriptional/mRNA level rather than at the protein stabi-
lity level (Figure 4b). To address deeper the molecular
mechanism by which BNC2 is regulated in an oxidative stress
condition, we investigated the role of epigenetic modifica-
tions in BNC2 expression at different time points after H2O2
exposure. To do this, we performed a time-course experi-
ment in COV318 treated with 0.06 mM of H2O2, which is the
lowest dosage at which we previously observed a reduction
of BNC2 protein expression levels, and we confirmed that
BNC2 expression decreases both at mRNA and protein
levels (Figures 4c and d). As BNC2 promoter contains three
CpG islands (Supplementary Figure S3) and BNC2 pro-
moter methylation has been previously found associated
with EOC,22 we analyzed methylation status of CpG island
141 (chr9:16870124–16872020 hg19) and CpG island
21 (chr9:16828936–16829169 hg19) and did not observe
any methylation both in untreated and treated cells (data
not shown). Concomitantly, we evaluated activating and
repressing histone modifications (H3K4me3 and H3K27me3,
respectively) in the same time-course experiment. Unexpect-
edly, activating H3K4me3 modification increased at earlier
time points and eventually decreased at 24 h (Figure 4e),
whereas we did not find any enrichment of repressing
H3K27me3 modification (data not shown). We also wondered
whether BNC2 repression persisted longer than 24 h after
H2O2 exposure; indeed, we found BNC2 downregulation
both at mRNA and protein levels lasting up to 1 week
post-treatment (Figures 4f and g), likely due to a decrease
of activating H3K4me3 enrichment and an increase of
suppressing H3K27me3 in BNC2 promoters and enhancers
(Figure 4h). Enrichment of H3K27me3 modification in
H2O2- treated COV318 cells was similar to OV90, which
constitutively do not express BNC2 (Figure 4h). According to
our results, decrease of BNC2 expression after H2O2 exposure
is not due to methylation and histone modifications at early
time points, whereas at later time points, histone modification
is involved in BNC2 transcription repression.
To study the effect of ovulation on BNC2 expression
levels in vivo, we induced superovulation in prepubertal
mice and measured BNC2 protein levels in murine oviducts.
In this model, BNC2 displayed several protein isoforms
similarly to COV318, and its protein expression levels
decreased in ovulated mice compared with control mice
(Figure 4i).
To sum up, these evidences suggest that BNC2 expression
levels decrease both in vitro and in vivo after oxidative stress or
ovulation, respectively.
Figure 4 Oxidative stress reduces BNC2 expression in vitro and in vivo. (a) Western blot detection of BNC2 protein levels in NP40-insoluble extracts from COV318 and
COV504 cells treated with increasing amounts of H2O2 (0.06, 0.125 and 0.25 mM) at 3 or 24 h post-treatment. Total H2AX was used as loading control. Phospho-H2AX (pH2AX)
was detected to check effectiveness of H2O2 treatment. (b) qRT-PCR analysis of BNC2 expression in COV318 and OVCAR4 at 5 h after H2O2 treatment. Bars indicate mean±
S.E. from two independent experiments. (c) Western blot detection of BNC2 protein levels in NP40-insoluble extracts from COV318 cells treated with 0.06 mM H2O2 and collected
1, 6 and 24 h post-treatment. Total H2AX was used as loading control. pH2AX was detected to check effectiveness of H2O2 treatment. (d) qRT-PCR analysis of BNC2 expression
in COV318 at 1, 6 and 24 h after 0.06 mM H2O2 treatment. Bars indicate mean±S.E. from two independent experiments. (e) ChIP for H3K4me3 enrichment (measured by qRT-
PCR) of three regulatory elements of BNC2 locus in COV318 treated with 0.06 mMH2O2 at different time points. Bars indicate mean± S.E. from two independent experiments. (f)
Western blot detection of BNC2 protein levels in NP40-insoluble extracts from COV318 cells treated with 0.06 mM H2O2 and collected 1 week post-treatment. Total H2AX was
used as loading control. pH2AX was detected to check effectiveness of H2O2 treatment. (g) qRT-PCR analysis of BNC2 expression in COV318 at 1 week after 0.06 mM H2O2
treatment. Bars indicate mean± S.E. from two independent experiments. (h) ChIP for H3K4me3 enrichment (left panel) and H3K27me3 enrichment (right panel) (measured by
qRT-PCR) of three regulatory elements of BNC2 locus in COV318 at 1 week after 0.06 mM H2O2 treatment. Bars indicate mean± S.E. from two independent experiments. (i) Left
panel: Western blot detection of BNC2 protein levels in NP40-insoluble extracts from prepubertal mice oviducts treated or not with hCG 16 h earlier. COV318 was used as positive
control for BNC2 expression. Right panel: Densitometric analysis of BNC2 western blot bands in oviducts from hCG treated (n= 10) and untreated (n= 10) prepubertal mice as
described above. Scatter dot plot bars indicate mean±S.E. from two independent experiments, including the one presented in the left panel. *Po0.05
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BNC2 silencing increases ovarian cell survival following
H2O2 treatment. Next, we argued whether BNC2 levels
affect cell survival after oxidative stress. To this aim, we
treated OV90 (no BNC2 expression), OVCAR4 (intermediate
BNC2 expression) and COV318 (high BNC2 expression)
(Figure 2b) with increasing doses of H2O2; 24 h after treat-
ment, we measured surviving cells by MTT assay. Interest-
ingly, we observed that OV90 cells are resistant to H2O2
treatment (480% alive); at the same dosages, OVCAR4 and
COV318 showed a degree of H2O2 sensitivity that was
inversely correlated with BNC2 expression levels (Figure 5a).
With this observation in mind, we silenced BNC2 levels by
shRNA in three different BNC2-expressing HGSOC cell
lines and in BNC2-null OV90 cell line. We tested five short
hairpins spanning different regions of BNC2 (Supplementary
Figure S3), and used the ones with a strong and intermediate
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silencing ability (sh3 and sh5) for further experiments
(Figure 5b and Supplementary Figure S6A). When we
treated BNC2-silenced cells with H2O2, we observed that
silenced cells were more resistant to H2O2 compared with
control cells in three HGSOC cell lines (Figure 5c); this effect
was not recapitulated in OV90 (Supplementary Figure 6B),
which are null for BNC2, indicating that the phenotype that we
described was BNC2-specific. Cells silenced with sh5, which
always displayed the smallest BNC2 reduction, were also
the ones with the smallest increase in cell survival, implying
that the effect that we observed was dependent on BNC2
expression levels.
In conclusion, these evidences indicate that low BNC2
expression levels have a protective role in response to H2O2,
which is in line with reduced expression levels of BNC2 in
HGSOC compared with control samples (Figures 1b–d).
Discussion
Our study showed that the first intron and exon of BNC2 and
one of its promoters are in linkage with rs3814113, and that
BNC2 expression levels were reduced in HGSOC samples
compared with control samples. Moreover, we observed that
deletion of 5 kb surrounding rs3814113 decreased BNC2
expression levels in an isogenic cell line and, finally, that
silencing of BNC2 expression levels increased HGSOC cell
survival after H2O2 treatment.
Altogether, our findings give new insights about the mecha-
nism at the basis of HGSOC and 9p22.2 association,14 and in
particular they suggest that the intergenic region located
around rs3814113 regulates BNC2 expression, which in turn
affects cell survival after oxidative stress response. Indeed,
HGSOC samples present lower BNC2 expression levels that,
Figure 5 BNC2 silencing increases ovarian cancer cell survival following H2O2 treatment. (a) MTT viability, expressed as fold change compared with untreated cells (= 1), of
OV90, OVCAR4 and COV318 cells 24 h following H2O2 treatment. **Po0.01, *Po0.05 using t-test assuming unequal variances. Points in graph represent average± S.E. of
three independent biological replicates. (b) Western blot detection of BNC2 protein levels in NP40-insoluble extracts from COV318, COV362 and COV504 expressing five different
short hairpins (sh) targeting BNC2. shNT= sh non-target, negative control. (c) Scatter dot plot resume MTT viability experiments, expressed as fold change compared with
untreated cells (= 1), of COV318, COV362 and COV504 silenced (sh3 and sh5) or not (shNT) for BNC2 24 h following H2O2 treatment. **Po0.01, *Po0.05 using one-way
analysis of variance (ANOVA) test. Scatter dot plot bars indicate mean± S.E. of four replicates (two independent biological experiments performed in duplicate). Results from
different H2O2 treatments for each cell line are shown: COV318 (0.5 mM), COV362 (0.75 mM) and COV504 (0.25 mM)
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in the initial phases of oncogenic transformation, may confer
resistance to oxidative stress and ultimately reduce the
clearance of cells with ROS-induced damages.
So far, few groups have published results regarding the
role of BNC2 in cancer, but all suggested a putative tumor
suppressor function of BNC2,24–26 in agreement with our
findings. Ramus et al.36 reported that rs3814113 minor allele
(C) is also associated to a lower risk of EOC in BRCA1/2-
mutated populations. When we analyzed the gene expression
data set from Tone et al.,28 which contains both BRCA1/2WT
andmutant control samples, we did not observe any difference
in BNC2 expression levels between the two groups (data not
shown). Ultimately, these evidences may suggest that BNC2
locus and BRCA1/2 loci are two independent risk factors in
EOC onset.
Our study presents some limitations: for instance, (1) we
used cell lines derived from HGSOC and not cell lines derived
from normal tissues (e.g. normal fallopian tubes); never-
theless, we confirmed our in vitro findings in the normal
oviducts obtained from a mouse model of superovulation. (2)
We did not investigate in our cell model the allele-specific
impact of rs3814113 on BNC2 expression, as we expected
that it would have taken a GWAS-size clones to observe any
effect. Instead, we took advantage of an isogenic cell line
knocked out for 5 kb interval surrounding rs3814113 to obtain
a stronger effect. Despite having found a link between
rs3814113 genomic region and BNC2 expression, we cannot
exclude that other genetic elements that are located in the
haplotypic block of rs3814113 participate in BNC2 regulation.
(3) Finally, even though we described that silencing of BNC2
expression affects survival after H2O2 treatment, despite our
attempts, we could not generate cells overexpressing BNC2 to
rescue silencing experiments and we did not dissect in greater
detail the molecular mechanism at the basis of this phenotype.
Precisely, our results on BNC2 localization in agreement
with19 suggest that BNC2 is localized in the nucleus more
firmly compared with transcription factors and is a putative
chromatin-modulating protein; therefore, ChIP-seq would be a
good approach to study BNC2 binding regions.
EOC and breast cancer share some common risk factors
(e.g. BRCA1/2 status); therefore, it might be expected
that BNC2 has a role also in breast cancer onset. We are
not aware of BNC2 expression levels in normal and tumor
breast samples; however, there is no report of any asso-
ciation between rs3814113 and breast cancer risk, in both
the general population15 and BRCA1/2 mutant carriers,36
ultimately suggesting that BNC2 is not involved in breast
cancer.
According to our results, BNC2 seems to be a good
candidate to develop new molecular tools to select healthy
subjects with increased risk of EOC. Despite having demon-
strated that the 5 kb region around rs3814113 regulatesBNC2
expression, it is unlikely that we can use rs3814113 genotyp-
ing as an indicator of BNC2 expression14 and novel strategies
should be undertaken. At the same time, we showed that
BNC2 silencing affects cell survival after oxidative stress,
which suggests that modulating BNC2 levels pharmacologi-
cally may be an intriguing strategy to reduce the excess of
EOC risk in selected populations (e.g. BRCA1/2 mutation
carriers). Ultimately, if we consider that the discovery of high
penetrance risk alleles (BRCA1/2 mutations) not only helped
to identify subjects at higher risk but it was also helpful to select
EOC patients benefiting the most from poly(ADP-ribose)
polymerase inhibitors,5 the same scenario may also be true
for BNC2. Hence, understanding how to target BNC2 and/or
the associated stress response pathway could lead to the
development of alternative therapeutic approaches for
patients with HGSOC.
Materials and Methods
Cell lines, cell cultures, lentiviral transduction and transfections.
Cell lines used in this work are listed in Supplementary Table 2, which includes cell
type, source and culture media. No antibiotics were routinely used for cell culture.
Cells have been authenticated in 2012 by BMR Genomics (Padova, Italy) according
to Cell ID System (Promega, Madison, WI, USA) and using Genemapper ID version
3.2.1, to identify DNA STR profiles. Cells were expanded and have been used only
for a short number of passages after authentication. Cell lines were maintained at
37 °C under 5% CO2 in humidified incubators and routinely tested using MycoAlert
Detection Kit (Lonza, Cologne, Germany) for mycoplasma contamination. Only
mycoplasma-negative cells were used for experiments.
BNC2-silenced ovarian cancer cell lines were generated by lentiviral transduction.
Briefly, 293FT cells were co-transfected with pLKO.1 puro vectors encoding for
either human BNC2-shRNAs (sh1_TRCN0000108177, sh2_TRCN0000327841
sh3_TRCN0000108179, sh4_TRCN0000108175, sh5_TRCN0000108176, MISSION
shRNAs from Sigma-Aldrich (St. Louis, MO, USA)) or non-target shRNA control
(SHC016; Sigma-Aldrich), together with ViraPower Packaging Mix (pLP1, pLP2
and pLP/VSV-G) (Invitrogen, Thermo Fisher Scientific, Eugene, OR, USA). Viral
supernatants were collected 72 h later and transducing units per ml were determined
by limiting dilution titration in HCT116 cells. An MOI of ~ 5 was used for transducing
ovarian cancer cells. After 5 days of selection with puromycin, BNC2-silenced cells
were immediately used for in vitro experiments, protein and RNA extraction.
Polybrene (Sigma-Aldrich) at a final concentration of 8 μg/ml was used to increase
transduction efficiency.
Cell transfections were performed using Lipofectamine 2000 reagent (Invitrogen,
Thermo Fisher Scientific) according to the manufacturer’s instructions.
CRISPR-Cas9 system. KO of AK024561 in 293FT cells was generated by
CRISPR-Cas9 system, according to Ran et al.,34 using two guide RNAs (guides 6
and 9; Supplementary Table 3) that delimit a region of 5 kb surrounding the
AK024561 non-coding transcript (Figure 3a). To this end, guide RNAs were cloned
into pSpCas9(BB)-2A-GFP (PX458) vector (cat. no. 48138; Addgene, Cambridge,
MA, USA) and transfected into cells. To evaluate guide RNA-directed Cas9 cutting
efficiency, genomic DNA was extracted using Gentra Puregene Cell Kit (Qiagen
Sciences, Germantown, MD, USA), according to the manufacturer’s instructions,
and was subjected to Surveyor Assay using Surveyor Mutation Detection Kit (IDT
Integrated DNA Technologies, Leuven, Belgium), as per the manufacturer’s
instructions (Supplementary Figure 4A).
The 293FT CRISPR-modified cell clones were grown following GFP single-cell
sorting by FACS, then genomic DNA was extracted and clones were screened by
PCR, using two primers, AK024561 5+3 and Screen 6F+7R (Figure 3a and
Supplementary Table 3), which for KO clones were expected to yield no product and a
1.6 kb fragment, respectively (Figure 3c and Supplementary Figure S4). Genetic
deletion was confirmed by direct Sanger sequencing, using BigDye Terminator v.3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Sequences of all
the clones that we used are reported in Supplementary Material.
Cell treatments. H2O2 treatment was performed as follows: cells plated 24 h
earlier in a 6- or 12-well format were exposed for 1 h to H2O2 (0–4 mM range) in
serum-free medium. After two washes with PBS, H2O2 containing medium was
removed and replaced with complete medium. Cell viability was assed 24 h later by
MTT staining (M2003; Sigma-Aldrich). MTT stock solution was added to cells at a
final concentration of 0.28 mg/ml and incubated for 1 h at 37 °C. Supernatant was
then discarded and cells were air-dried. Reduced MTT, measure of cellular
metabolic activity and index of cell viability was dissolved by adding 1 or 2 ml of
DMSO, depending on plate format. Two hundred microliters of DMSO were
transferred to a 96-well and absorbance was measured at 570 nm with Infinite
M1000 Microplate Reader (Tecan, Männedorf, Switzerland).
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Western blotting. To obtain protein extracts, cells were incubated for 20 min
on ice in lysis buffer (0.5% NP40, 50 mM HEPES, 250 mM NaCl, 5 mM EDTA,
0.5 mM EGTA, 1 μM DTT), containing Protease Inhibitors (Complete; Roche,
Mannheim, Germany) and Phosphatase Inhibitor Cocktail 1 and 2 (P2850 and
P5726; Sigma-Aldrich), vortexing every 5 min. Cell lysates were clarified by
centrifugation at a maximum speed for 10 min (NP40-soluble fraction). Cell pellet
was then suspended in SDS lysis buffer (4% SDS, 100 mM Tris-HCl (pH 6.8), 20%
glycerol) and boiled at 95 °C for 10 min (NP40-insoluble fraction, containing
chromatin-bound proteins, such as BNC2). Protein concentration of the NP40-
soluble fraction was quantified using the Protein Assay Dye Reagent Concentrate
(Bio-Rad, Hercules, CA, USA), whereas the concentration of the NP40-insoluble
fraction was empirically derived from its corresponding soluble fraction.
For immunoblotting analysis, ~ 40 μg of proteins were separated using 4–20%
SDS-PAGE Criterion TGX Stain-Free Precast Gels (Bio-Rad) and transferred to
PVDF membranes (Bio-Rad). Membranes were blocked with 5% non-fat dried milk in
TBS-0.1% Tween-20, and incubated overnight with the following antibodies: BNC2
(HPA018525; Sigma-Aldrich), ACTIN (cat. no. A2066; Sigma-Aldrich), histone
H2AX (cat. no. 2595; Cell Signaling, Danvers, MA, USA) and phospho-histone H2AX
(Ser139) (20E3) (cat. no. 2577; Cell Signaling). Incubation with ECL rabbit IgG,
HRP-linked whole antibody (GE Heathcare Lifesciences, Little Chalfont, UK) was
performed at room temperature for 1 h at a dilution of 1 : 3000. According to signal
intensity, either ECLWestern Blotting Detection Reagents RPN 2106 (GE Healthcare)
or Luminata Forte Western HRP Substrate (Merck Millipore, Darmstadt, Germany)
were used for secondary antibody detection using Chemidoc MP Imager (Bio-Rad).
Bands were analyzed and quantified using Image Lab v.5.2 (Bio-Rad).
ChIP assay. Before harvesting, 3x107 cells were crosslinked with 1% (v/v) of
formaldehyde in complete culture medium for 10 min at room temperature and then
quenched with 125 mM glycine. Cell pellets were washed two times with ice-cold
PBS and then lysed in 1 ml of ChIP lysis buffer (1% SDS, 50 mM Tris-HCl (pH 8.1),
10 mM EDTA), completed with Protease Inhibitors (Complete; Roche) and
Phosphatase Inhibitor Cocktail 1 (P5726; Sigma-Aldrich). Lysates were sonicated
with an ultrasonic homogenizer Sonopuls 3200 (Bandelin, Berlin, Germany) for 12
cycles (30 s ON+60 s OFF) and clarified by centrifugation. DNA fragment size was
checked in a 2% agarose gel with a 100 bp DNA marker. Fifty micrograms of
protein extract, diluted 10-fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1) and 167 mM NaCl), were
incubated, for 2 h with rotating at 4 °C, with 2 μg of the following specific ChIP grade
antibodies: anti-histone H3-acetyl K27, H3 tri-methyl K4 (cat. no. ab4729, ab8580;
Abcam, Cambridge, UK) and H3 tri-methyl K27) (cat. no. 9733; Cell Signaling).
Immunoprecipitation was performed by using Protein A Sepharose 4 Fast Flow (GE
Healthcare) overnight at 4 °C. After several washes of the IP samples (in low salt, in
high salt and in LiCl wash buffers), the elution was performed incubating in 1% SDS
and 100 mM NaHCO3 for 45 min with rotation at room temperature. To reverse
crosslinking, supernatants were collected and incubated at 65 °C overnight with the
addition of NaCl, 200 mM final concentration. Samples were subjected to DNA
extraction using Gentra Puregene Cell Kit (Qiagen) according to the manufacturer’s
instructions. DNA levels for the 9p22.2 regions of interest were quantified by qRT-
PCR using specific primers (Supplementary Table 3).
RNA extraction, cDNA synthesis and qRT-PCR. RNA was extracted
using the Isol-RNA lysis reagent (5 Prime, Hamburg, Germany) according to
protocol instructions. Extraction was followed by PCA (phenol: chloroform: isoamyl
alcohol 25 : 24 : 1; Sigma-Aldrich) purification that reduces salt contamination and
by DNase digestion (Turbo-Dnase, Ambion, Thermo Fisher Scientific). RNA quality
was assessed using agarose gel electrophoresis after RNA exposure to 70 °C for
5 min. cDNA was synthesized from 1 μg of RNA using the AMV Reverse
Transcriptase (Promega) with random primers (Promega). cDNA was diluted 10
times and used for qRT-PCR using iQ SYBR Green Supermix (Bio-Rad) with the
appropriate primers (Supplementary Table 3). qRT-PCR reactions were carried out
either in a 96-well optical reaction plates using Two-Color Real-Time PCR Detection
System MyiQ2 (Biorad) or in 384-well optical reaction plates using Applied
Biosystems 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific),
according to manufacturer's protocol. The 2−ΔΔCt method was used to calculate
the relative abundance of RNA genes, measuring GAPDH expression as
housekeeping control.
Primers used in this work were designed using Primer 3 Plus,37 purchased from
Sigma-Aldrich and are listed in Supplementary Table 3.
In vivo experiments. Prepubertal FVB female mice (between 3 and 5 weeks of
age) were stimulated with 5 μIU of serum gonadotropin (Folligon, Schering-Plough
Animal Health, Upper Hutt, Wellington, New Zealand) and 48 h later with 5 μIU of
human chorionic gonadotropin (Chorulon, MSD Animal Health, Madison, NJ, USA) or
with placebo (0.9% NaCl) by intraperitoneal injection. After 16 h, mice were humanely
culled, assessed for ovulation and oviducts were collected. NP40-soluble and
-insoluble proteins were extracted from oviducts, as described above. Animal
experiments were reviewed and approved by the CRO Aviano’s Institutional Animal
Care and Use Committee and were conducted according to committee’s guidelines.
Patient samples. Samples were obtained at CRO Aviano, National Cancer
Institute (Aviano, Italy) according to Cervo et al.,38 after informed consent forms
were signed, through CRO-Biobank facility. Scientific use of biological material was
approved by CRO Aviano’s Ethics Committee and Internal Review Board. Control
ovarian and fallopian tube samples were collected from women undergoing
annexectomy for diseases other than ovarian and fallopian tubes cancers, whereas
HGSOC specimens were collected from ovarian cancer patients undergoing first-
line cytoreductive surgery (by laparoscopy or laparotomy). CRO Aviano’s Pathology
Unit performed sample pathologic evaluation as part of standard routine on fresh-
frozen specimens and confirmed a tumor percentage 470%.
Statistical and gene expression analysis. Graphs presented in figures
were obtained using the GraphPad Prism v.6.0d software (La Jolla, CA, USA) and
statistical analysis were carried out using the JMP v.9.0.1 software (Carry, NC,
USA). Data were examined using the two-tailed Student's t-test assuming unequal
variances or one-way ANOVA test when we compared more than two groups at
once. Differences were considered significant at Po0.05 and Po0.01 and labeled
accordingly (* or **, respectively).
Data sets used for gene expression analysis include Gene Expression Omnibus
IDs: GSE1097128 and GSE26712.29 For each set, gene signal values were
background corrected, normalized by the quantile method and reported as log 2-
transformed values, as implemented in the rma function of the Affy R package.
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